LicianPro

REGENXBIO Inc. ·

RGNX 8-K 2026-09-23

REGENXBIO Inc. (RGNX) 8-K dated 2026-09-23 — accession 0001193125-26-399377.

REGENXBIO Inc. (RGNX) is a biotechnology company listed on US.

REGENXBIO Inc. filed a 8-K on 2026-09-23. Accession 0001193125-26-399377.

This 8-K covers: Material agreement (Item 1.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported RGNX revenue for 2025-12-31 was $170.4M. Net income was -$193.9M. Revenue was up 104.5% from 2024-12-31 to 2025-12-31. RGNX currently screens at market cap $440.4M.

Not investment advice. The RGNX SEC hub lists recent forms. The stock page is the research view.

Open on SEC EDGAR

These filings as JSON? API free 100/day

Lician Pro $19.99/mo or $149/yr